EW Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences Corporation Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.
और पढ़ें
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.
History
Edwards Lifesciences was originally founded by electrical engineer Miles "Lowell" Edwards in 1958, a graduate of Oregon State University. Edwards invented the first medically proven and adopted artificial heart valve. Dr. Albert Starr, a surgeon at the Oregon Health and Sciences University, is credited as the first to successfully implant the Starr-Edwards mitral valve in a patient in 1960. As a result of the successful heart implant, Edwards established manufacturing in Santa Ana, California the same year to continue his research in pulmonary devices.
Edwards' valves are still in operation today. An early patient lived a record 48 years with the implant before requiring a replacement.
Edwards was acquired by Baxter in 1985. It was spun off from Baxter in 2000.
In 2017, Edwards completed the acquisition of Valtech Cardio for $340 million. Also in 2017, Edwards acquired Harpoon Medical of Baltimore, Maryland for $100 million. Harpoon, founded in 2013, developed a minimally invasive heart surgery product for mitral valve repair to treat degenerative mitral regurgitation. At the time of the acquisition, the product was not available on any market.
On April 18, 2019, Edwards completed the acquisition of CAS Medical Systems of Branford, Connecticut for ~$100 million.
Edwards Sapien 3 and Sapien 3 Ultra Transcatheter Heart Valve systems were FDA-approved for the treatment of patients at low risk for death or major complications associated with open-heart surgery on August 16, 2019. These products are used to treat patients with severe aortic stenosis without utilizing open-heart surgery.
In 2020, Edwards co-sponsored the Virtual ISPOR-FDA Summit centered on patient preference information in medical device regulatory decisions.
In December 2021, the FDA approved the SAPIEN 3 transcatheter valve in combination with the Alterra adaptive prestent for the treatment of severe pulmonary regurgitation.
In February 2024, the FDA approved Edwards' EVOQUE tricuspid valve replacement system, the first transcatheter therapy approved in the United States for the treatment of tricuspid regurgitation. In May 2024, Edwards launched the SAPIEN 3 Ultra RESILIA valve in Europe.
In June 2024, the company received FDA approval for a new implant designed to manage heart failure issues, called the Cordella pulmonary artery sensor.
In July 2024, Edwards made agreements with Affluent Medical for an equity stake, IP licensing and an exclusive option to acquire its Kephalios subsidiary. The same month, Edwards announced it would acquire Innovalve Bio Medical for approximately $300 million, and JenaValve Technology and Endotronix for $1.2 billion.
In August 2024, Edwards acquired JC Medical from Genesis MedTech, gaining its J-Valve transcatheter aortic valve replacement system for the treatment of aortic regurgitation.
In 2023, Edwards announced that its critical care business unit would be spun off into a separate entity. In June 2024 Edwards instead agreed to sell the unit to BD for $4.2 billion. The sale closed on September 3, 2024.
In May 2025, the FDA approved the SAPIEN 3 platform, including the SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA valves, for the treatment of severe aortic stenosis in asymptomatic patients, marking the first FDA approval of TAVR therapy for this patient population.
In September 2025, Edwards completed the full acquisition of heart failure monitoring company Vectorious Medical Technologies.
In January 2026, the FDA approved the SAPIEN M3 mitral valve replacement system, the first transcatheter mitral valve replacement therapy using a transseptal approach to receive FDA approval for the treatment of mitral regurgitation.
Business segments
Prior to September 2024, its products were categorized into four areas: surgical valve technologies, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and critical care. In September 2024, Edwards completed the sale of its Critical Care product group to BD. Since September 2024, its products are categorized into four areas: surgical valve technologies, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and implantable heart failure management (IHFM).
Transcatheter Heart Valve
The company's SAPIEN family of transcatheter aortic heart valves is made of bovine pericardial tissue mounted within a balloon-expandable, cobalt-chromium frame and is deployed via catheter. Edwards introduced the transcatheter heart valve replacement procedure to U.S. patients unable to undergo open-heart surgery with FDA approval of the SAPIEN transcatheter valve in 2011. The indication was expanded in November 2012 to include patients at a high risk for death or serious complications associated with open-heart surgery. In 2021, the FDA cleared Edwards’ SAPIEN 3 transcatheter valve with the Alterra adaptive prestent for pulmonic heart valve replacement. In May 2024, Edwards launched the SAPIEN 3 Ultra RESILIA valve in Europe.
Transcatheter Mitral and Tricuspid Therapies
The Transcatheter Mitral and Tricuspid Therapies business segment develops transcatheter heart valve repair and replacement technologies to treat mitral and tricuspid valve diseases. In September 2022, the FDA approved Edwards' PASCAL Precision transcatheter valve repair system for the treatment of degenerative mitral regurgitation.
Surgical
The Surgical business segment involves the use of Edwards' RESILIA tissue technology, developed to help limit valve calcification. Edwards estimates that more than 450,000 patients around the world have either undergone SAVR or TAVR with an Edwards RESILIA valve.
Critical Care
Before its sale, the Critical Care business segment included pulmonary artery catheters, disposable pressure transducers and advanced hemodynamic monitoring systems. The portfolio also included a line of balloon catheter-based vascular products, surgical clips and inserts. In 2023, it was announced that the critical care business unit was to be spun off into its own entity, however in 2024 the critical care department was purchased by BD for $4.2 billion.
Organizational culture
Edwards Lifesciences Foundation
The Edwards Lifesciences Foundation launched in 2014 and supports programs designed to treat underserved people to reduce heart valve disease.
Since the initiative launched in 2014, Edwards and its foundation have contributed more than $100 million in financial and technology donations through "Every Heartbeat Matters" (EHM), reaching over 4 million underserved structural heart patients globally.
स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗
EW स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा
EW स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें
10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान
मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?
लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC
वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती
विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR
पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर
EW विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड
- मजबूत खरीद 13 32.5%
- खरीदें 17 42.5%
- होल्ड 10 25.0%
- बेचें 0 0.0%
- मजबूत बिक्री 0 0.0%
12-महीने का मूल्य लक्ष्य
26 विश्लेषक · 2026-08-19Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि
| Period | EPS Actual | EPS अनुमान | आश्चर्य |
|---|---|---|---|
| 30 जून 2026 | $0.78 | $0.76 | 0.02% |
| 31 मार्च 2026 | $0.78 | $0.75 | 0.03% |
| 31 दिसमबर 2025 | $0.58 | $0.64 | -0.06% |
| 30 सितमबर 2025 | $0.67 | $0.61 | 0.06% |
| 30 जून 2025 | $0.67 | $0.64 | 0.03% |
| 31 मार्च 2025 | $0.64 | $0.61 | 0.03% |
सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी
| टिकर | मार्केट कैप | P/E | राजस्व YoY | शुद्ध मार्जिन | ROE | सकल मार्जिन |
|---|---|---|---|---|---|---|
| EW | $49.50B | 46.6 | 11.6% | 17.7% | 10.6% | 78.0% |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | — |
| ISRG | $201.11B | 72.0 | 20.5% | 28.4% | 16.7% | 66.0% |
| SYK | $134.44B | 41.8 | 11.2% | 12.9% | 15.1% | 64.0% |
| BSX | — | 49.1 | 19.9% | 14.4% | 12.6% | 69.0% |
| BDX | — | 25.3 | 8.2% | 7.7% | 6.5% | — |
| IDXX | $53.93B | 51.7 | 10.4% | 24.6% | 69.2% | 61.8% |
| DXCM | $25.54B | 31.8 | 15.6% | 17.9% | 31.4% | 60.1% |
| GEHC | — | 18.0 | 4.8% | 10.1% | 22.1% | 40.0% |
| RMD | $28.11B | 18.7 | 9.8% | 26.9% | 23.6% | 61.1% |
| ZBH | $28.66B | 25.3 | 7.2% | 8.6% | 5.6% | — |
पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह
आय विवरण 17
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B | $4.35B | $3.72B | $3.44B | $2.96B | $2.49B | $2.32B | |
| Cost of Revenue | $1.33B | $1.12B | $978M | $724M | $1.25B | $1.08B | $1.11B | $939M | $875M | $797M | $617M | $626M | |
| Gross Profit | $4.73B | $4.32B | $4.03B | $3.74B | $3.98B | $3.31B | $3.23B | $2.78B | $2.56B | $2.17B | $1.88B | $1.70B | |
| R&D Expense | $1.08B | $1.05B | $963M | $844M | $903M | $761M | $753M | $622M | $553M | $442M | $383M | $346M | |
| SG&A Expense | $2.09B | $1.79B | $1.58B | $1.36B | $1.49B | $1.23B | $1.24B | $1.09B | $991M | $905M | $851M | $858M | |
| Operating Income | $1.26B | $1.38B | $1.31B | $1.50B | $1.69B | $898M | $1.15B | $748M | $1.09B | $751M | · | · | |
| Interest Expense | · | · | $18M | $19M | $18M | $16M | $21M | $30M | $23M | $19M | $17M | $17M | |
| Interest Income | $169M | $120M | $67M | $36M | $17M | $23M | $32M | $32M | $20M | $11M | $8M | $6M | |
| Other Non-op | $7M | $69M | $14M | $5M | $13M | $12M | $8M | $4M | $-1M | $-5M | $-4M | $-8M | |
| Pretax Income | $1.27B | $1.55B | $1.37B | $1.52B | $1.70B | $917M | $1.17B | $761M | $1.03B | $738M | $622M | $1.14B | |
| Income Tax | $217M | $152M | $152M | $196M | $199M | $93M | $120M | $39M | $451M | $168M | $128M | $333M | |
| Net Income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | · | · | · | · | · | · | · | |
| EPS (Basic) | $1.84 | $6.98 | $2.31 | $2.46 | $2.41 | $1.32 | $1.68 | $1.15 | $2.77 | $2.67 | $2.30 | $3.81 | |
| EPS (Diluted) | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 | $2.70 | $2.61 | $2.25 | $3.74 | |
| Shares (Basic) | 584,800,000 | 597,700,000 | 606,700,000 | 619,000,000 | 623,300,000 | 622,600,000 | 624,800,000 | 627,600,000 | 210,900,000 | 213,000,000 | 215,500,000 | 213,000,000 | |
| Shares (Diluted) | 585,800,000 | 599,300,000 | 609,400,000 | 624,200,000 | 631,200,000 | 631,900,000 | 636,700,000 | 640,900,000 | 215,900,000 | 217,800,000 | 220,300,000 | 217,000,000 | |
| EBITDA | $1.42B | $1.53B | $1.68B | $1.89B | $1.83B | $1.00B | $1.24B | $826M | $82M | $71M | $66M | $69M |
बैलेंस शीट 29
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.94B | $3.05B | $1.13B | $769M | $863M | $1.18B | $1.18B | $714M | $818M | $930M | $718M | $654M | |
| Short-term Investments | $1.29B | $931M | $500M | $446M | $604M | $219M | $338M | $242M | $519M | $341M | $506M | $785M | |
| Receivables | $660M | $609M | $772M | $643M | $582M | $515M | $544M | $457M | $439M | $366M | $315M | $288M | |
| Inventory | $1.13B | $1.09B | $904M | $876M | $727M | $802M | $641M | $607M | $555M | $397M | $340M | $297M | |
| Prepaid Expense | $135M | $121M | $129M | $110M | $85M | $75M | $59M | $54M | $61M | $46M | $45M | $49M | |
| Other Current Assets | $339M | $348M | $225M | $196M | $237M | $208M | $168M | $132M | $117M | $112M | $66M | $122M | |
| Current Assets | $6.74B | $6.29B | $4.04B | $3.10B | $3.18B | $3.09B | $2.98B | $2.29B | $2.55B | $2.24B | $2.05B | $2.23B | |
| PP&E (Net) | $1.81B | $1.69B | $1.59B | $1.63B | $1.55B | $1.40B | $1.06B | $868M | $680M | $580M | $482M | $443M | |
| PP&E (Gross) | $2.66B | $2.48B | $2.29B | $2.38B | $2.20B | $1.99B | $1.57B | $1.32B | $1.09B | $961M | $854M | $808M | |
| Accum. Depreciation | $850M | $794M | $699M | $750M | $655M | $598M | $512M | $455M | $412M | $381M | $372M | $365M | |
| Goodwill | $1.77B | $1.78B | $1.15B | $1.06B | $1.17B | $1.17B | $1.17B | $1.11B | $1.13B | $626M | $628M | $376M | |
| Intangibles | $1.13B | $1.18B | $399M | $285M | $324M | $331M | $336M | $343M | $468M | $205M | $205M | $23M | |
| Other Non-current Assets | $730M | $722M | $463M | $299M | $111M | $120M | $102M | $34M | $109M | $123M | $132M | $49M | |
| Total Assets | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B | $7.24B | $6.49B | $5.32B | $5.67B | $4.51B | $4.06B | $3.52B | |
| Accounts Payable | $228M | $197M | $187M | $202M | $204M | $196M | $180M | $134M | $117M | $97M | $64M | $58M | |
| Current Liabilities | $1.81B | $1.51B | $1.20B | $1.02B | $1.03B | $894M | $902M | $877M | $1.42B | $532M | $476M | $426M | |
| Capital Leases | $83M | $79M | $65M | $70M | $69M | $73M | $59M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $37M | · | · | · | · | · | |
| Other Non-current Liabilities | $362M | $373M | $251M | $218M | $267M | $252M | $203M | $150M | $147M | $115M | $285M | $113M | |
| Total Liabilities | $3.36B | $2.99B | $2.64B | $2.49B | $2.67B | $2.66B | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | · | · | · | $594M | $1.04B | $822M | · | · | |
| Total Debt | $598M | $598M | $597M | $596M | $596M | $595M | $594M | $594M | $1.04B | $822M | $600M | $598M | |
| Common Stock | $659M | $655M | $650M | $646M | $642M | $636M | $218M | $215M | $212M | $243M | $239M | $129M | |
| Retained Earnings | $14.24B | $13.17B | $8.99B | $7.59B | $6.07B | $4.57B | $3.74B | $2.69B | $1.96B | $3.91B | $3.34B | $2.84B | |
| Treasury Stock | $7.09B | $6.19B | $5.02B | $4.14B | $2.42B | $1.90B | $1.28B | $1.02B | $252M | $2.50B | $1.84B | $1.56B | |
| AOCI | $-238M | $-244M | $-243M | $-255M | $-158M | $-161M | $-156M | $-138M | $-133M | $-198M | $-183M | $-101M | |
| Stockholders' Equity | $10.34B | $10.00B | $6.65B | $5.81B | $5.84B | $4.57B | $4.15B | $3.14B | $2.96B | $2.62B | $2.50B | $2.19B | |
| Liabilities + Equity | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B | $7.24B | $6.49B | $5.32B | $5.67B | $4.51B | $4.06B | $3.52B | |
| Shares Outstanding | 580,700,000 | 654,800,000 | 650,500,000 | 646,300,000 | 642,000,000 | 636,400,000 | 218,100,000 | 207,700,000 | 209,700,000 | 211,600,000 | 215,400,000 | 107,800,000 |
नकदी प्रवाह 18
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $157M | $155M | $145M | $140M | $135M | $107M | $89M | $77M | $82M | $71M | $66M | $69M | |
| Stock-based Comp | $158M | $162M | $139M | $127M | $109M | $93M | $81M | $71M | $62M | $57M | $50M | $48M | |
| Deferred Tax | $-66M | $-163M | $-242M | $-262M | $-44M | $-52M | $10M | $-21M | $27M | $-24M | $-16M | $-67M | |
| Amort. of Intangibles | $8M | $6M | $2M | $2M | $8M | $5M | $5M | $2M | $8M | $8M | $7M | $8M | |
| Restructuring | $13M | $33M | · | · | · | · | · | · | · | · | $0 | $0 | |
| Other Non-cash | $273M | $-3.79B | $-529M | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $1.60B | $542M | $896M | $1.22B | $1.73B | $1.05B | $1.18B | $927M | $1.00B | $704M | $550M | $1.02B | |
| CapEx | $260M | $252M | $253M | $245M | $326M | $407M | $254M | $239M | $168M | $176M | $103M | $83M | |
| Investing Cash Flow | $-713M | $2.31B | $174M | $252M | $-1.72B | $-531M | $-596M | $77M | $-647M | $-212M | $-316M | · | |
| Debt Issued | · | · | $0 | $0 | $5M | $16M | $19M | $688M | $995M | $254M | $31M | $226M | |
| Net Debt Issued | · | · | $0 | $0 | $5M | $16M | $19M | $688M | $995M | $254M | $31M | $226M | |
| Stock Repurchased | $893M | $1.16B | $880M | $1.73B | $513M | $625M | $263M | $796M | $763M | $662M | $280M | $301M | |
| Net Stock Activity | $-893M | $-1.16B | $-880M | $-1.73B | $-513M | $-625M | $-263M | $-796M | $-763M | $-662M | $-280M | $-301M | |
| Financing Cash Flow | $-957M | $-983M | $-711M | $-1.58B | $-356M | $-487M | $-116M | $-1.10B | $-473M | $-268M | $-159M | · | |
| Net Change in Cash | $-119M | $1.91B | $375M | $-95M | $-333M | $16M | $468M | $-104M | $-112M | $212M | $65M | $233M | |
| Taxes Paid | $490M | $1.20B | $470M | · | · | · | · | · | · | · | · | $275M | |
| Free Cash Flow | $1.33B | $290M | $643M | $974M | $1.41B | $647M | $925M | $688M | $833M | $528M | $447M | $939M | |
| Levered FCF | · | · | $627M | $957M | $1.39B | $633M | $906M | $660M | $820M | $513M | $433M | $927M |
लाभप्रदता 8
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.0% | 79.5% | 77.0% | 79.9% | 76.1% | 75.4% | 74.4% | 74.8% | 74.5% | 73.1% | 75.2% | 73.1% | |
| Operating Margin | 20.8% | 25.4% | 25.6% | 32.5% | 32.3% | 20.5% | 26.4% | 20.1% | · | · | · | · | |
| Net Margin | 17.7% | 76.8% | 23.4% | · | · | · | · | · | · | · | · | · | |
| Pretax Margin | 21.0% | 28.5% | 26.6% | 32.8% | 32.5% | 20.9% | 26.8% | 20.4% | 30.1% | 24.9% | 25.0% | 49.2% | |
| EBITDA Margin | 23.4% | 28.2% | 28.0% | 35.1% | 34.9% | 22.9% | 28.4% | 22.2% | 2.4% | 2.4% | 2.6% | 2.9% | |
| ROA | 8.0% | 37.2% | 15.9% | · | · | · | · | · | · | · | · | · | |
| ROE | 10.6% | 50.1% | 22.5% | · | · | · | · | · | · | · | · | · | |
| ROIC | 9.6% | 11.7% | 18.5% | 23.5% | 23.2% | 15.6% | 21.7% | 19.0% | · | · | · | · |
तरलता और शोधन क्षमता 5
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 4.2 | 3.4 | 3.0 | 3.1 | 3.5 | 3.3 | 2.6 | 1.8 | 4.2 | 4.3 | 5.3 | |
| Quick Ratio | 2.7 | 3.0 | 2.0 | 1.8 | 2.0 | 2.1 | 2.3 | 1.6 | 1.3 | 3.1 | 3.2 | 4.0 | |
| Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.4 | 0.3 | 0.2 | 0.3 | |
| LT Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.3 | 0.2 | 0.3 | |
| Interest Coverage | · | · | 87.2 | 91.1 | 91.9 | 56.8 | 55.4 | 25.0 | · | · | · | · |
दक्षता 3
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.7 | 0.6 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | 1.2 | 1.1 | 1.4 | 1.3 | 1.6 | 1.5 | 1.8 | 1.6 | 1.8 | 2.2 | 1.9 | 2.1 | |
| Receivables Turnover | 9.6 | 7.9 | 8.5 | 8.8 | 9.5 | 8.3 | 8.7 | 8.3 | 8.7 | 8.7 | 8.3 | 7.9 |
विकास दरें 8
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.6% | 8.6% | 12.2% | -14.7% | 19.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 10.8% | 1.3% | 4.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.7% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -73.7% | 203.0% | -5.7% | 2.5% | 83.1% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -9.1% | 43.1% | 20.9% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -74.3% | 197.7% | -7.8% | 1.2% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -11.0% | 40.6% | · | · | · | · | · | · | · | · | · | · |
मूल्यांकन (TTM) 14
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B | $4.35B | $3.72B | $3.44B | $2.96B | $2.49B | $2.32B | |
| Net Income TTM | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | $235M | $235M | $235M | $235M | $235M | $235M | $235M | |
| Market Cap | $49.50B | $43.57B | $45.83B | $45.39B | $80.85B | $56.95B | $16.26B | $10.60B | $7.88B | $6.61B | $5.67B | $2.29B | |
| Enterprise Value | $45.88B | $40.20B | $44.79B | $44.77B | $79.98B | $56.15B | $15.34B | $10.24B | $7.58B | $6.16B | $5.05B | $1.45B | |
| P/E | 46.6 | 10.6 | 33.2 | 30.6 | 54.4 | 70.2 | 47.4 | 45.2 | 13.9 | 12.0 | 11.7 | 5.7 | |
| P/S | 8.2 | 8.0 | 9.1 | 10.2 | 15.5 | 13.0 | 3.7 | 2.8 | 2.3 | 2.2 | 2.3 | 1.0 | |
| P/B | 4.8 | 4.4 | 6.9 | 7.8 | 13.9 | 12.5 | 3.9 | 3.4 | 2.7 | 2.5 | 2.3 | 1.0 | |
| P / Tangible Book | 6.7 | 6.2 | 9.0 | 10.2 | 18.6 | 18.6 | · | · | · | · | · | · | |
| P / Cash Flow | 31.0 | 80.4 | 51.2 | 37.3 | 46.7 | 54.0 | 13.8 | 11.4 | 7.9 | 9.4 | 10.3 | 2.2 | |
| P / FCF | 37.1 | 150.3 | 71.3 | 46.6 | 57.5 | 88.0 | 17.6 | 15.4 | 9.5 | 12.5 | 12.7 | 2.4 | |
| EV / EBITDA | 32.3 | 26.2 | 26.7 | 23.7 | 43.8 | 55.9 | 12.4 | 12.4 | 92.5 | 86.5 | 76.7 | 21.1 | |
| EV / FCF | 34.4 | 138.7 | 69.7 | 46.0 | 56.9 | 86.7 | 16.6 | 14.9 | 9.1 | 11.7 | 11.3 | 1.5 | |
| EV / Revenue | 7.6 | 7.4 | 8.9 | 10.0 | 15.3 | 12.8 | 3.5 | 2.8 | 2.2 | 2.1 | 2.0 | 0.6 | |
| Earnings Yield | 2.1% | 9.4% | 3.0% | 3.3% | 1.8% | 1.4% | 2.1% | 2.2% | 7.2% | 8.4% | 8.6% | 17.6% |
आय विवरण 16
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.74B | $1.65B | $1.57B | $1.55B | $1.53B | $1.41B | $1.39B | $1.35B | $1.37B | $1.33B | $1.01B | $1.24B | $1.28B | $1.22B | $430M | $1.32B | |
| Cost of Revenue | $392M | $363M | $343M | $345M | $344M | $302M | $292M | $263M | $276M | $287M | $141M | $251M | $257M | $330M | $-99M | $254M | |
| Gross Profit | $1.35B | $1.29B | $1.23B | $1.21B | $1.19B | $1.11B | $1.09B | $1.09B | $1.09B | $1.04B | $870M | $993M | $1.03B | $992M | $529M | $1.07B | |
| R&D Expense | $279M | $263M | $268M | $281M | $276M | $255M | $271M | $253M | $272M | $257M | $215M | $243M | $244M | $261M | $131M | $234M | |
| SG&A Expense | $561M | $522M | $603M | $515M | $502M | $466M | $492M | $421M | $448M | $428M | $354M | $382M | $410M | $436M | $201M | $377M | |
| Operating Income | $513M | $478M | $151M | $307M | $411M | $395M | $313M | $351M | $366M | $349M | $291M | $366M | $264M | $388M | $198M | $402M | |
| Interest Income | $30M | $34M | · | · | $37M | $36M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-op | $17M | $72M | $3M | $3M | $-1M | $3M | $33M | $28M | $2M | $6M | $3M | $7M | $2M | $2M | $6M | $-2M | |
| Pretax Income | $520M | $459M | $90M | $348M | $400M | $434M | $390M | $403M | $384M | $371M | $311M | $388M | $275M | $399M | $211M | $407M | |
| Income Tax | $278M | $78M | $26M | $56M | $64M | $70M | $45M | $41M | $20M | $46M | $21M | $53M | $21M | $58M | $11M | $64M | |
| Net Income | $242M | $381M | $91M | $291M | $333M | $358M | $386M | $3.07B | $366M | $352M | $370M | $385M | $307M | $340M | $398M | $344M | |
| EPS (Basic) | $0.42 | $0.66 | $0.16 | $0.50 | $0.57 | $0.61 | $0.65 | $5.14 | $0.61 | $0.58 | $0.61 | $0.63 | $0.51 | $0.56 | $0.66 | $0.55 | |
| EPS (Diluted) | $0.42 | $0.66 | $0.16 | $0.50 | $0.56 | $0.61 | $0.65 | $5.13 | $0.61 | $0.58 | $0.61 | $0.63 | $0.50 | $0.56 | $0.65 | $0.55 | |
| Shares (Basic) | 576,400,000 | 579,200,000 | -1,173,800,000 | 584,700,000 | 587,000,000 | 586,900,000 | -1,203,200,000 | 597,200,000 | 602,100,000 | 601,600,000 | -1,214,700,000 | 607,000,000 | 606,900,000 | 607,500,000 | -1,243,800,000 | 619,800,000 | |
| Shares (Diluted) | 577,600,000 | 580,700,000 | -1,175,600,000 | 585,700,000 | 587,900,000 | 587,800,000 | -1,207,200,000 | 598,100,000 | 604,300,000 | 604,100,000 | -1,221,300,000 | 609,500,000 | 610,300,000 | 610,900,000 | -1,256,400,000 | 624,500,000 | |
| EBITDA | $513M | $518M | · | $307M | $411M | $431M | · | $351M | $369M | $426M | · | $418M | $327M | $424M | · | $402M |
बैलेंस शीट 27
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.91B | $2.45B | $2.94B | $2.69B | $3.27B | $3.14B | $3.05B | $3.68B | $1.64B | $1.22B | · | $1.41B | $1.04B | $872M | · | $1.25B | |
| Short-term Investments | $1.35B | $1.23B | $1.29B | $1.16B | $789M | $758M | $931M | $770M | $345M | $473M | · | $454M | $467M | $382M | · | $491M | |
| Receivables | $770M | $776M | $660M | $693M | $697M | $669M | $609M | $716M | $778M | $818M | · | $740M | $754M | $718M | · | $618M | |
| Inventory | $1.13B | $1.12B | $1.13B | $1.14B | $1.14B | $1.11B | $1.09B | $1.10B | $1.02B | $1.21B | · | $1.03B | $980M | $914M | · | $758M | |
| Prepaid Expense | $119M | $136M | $135M | $125M | $110M | $111M | $121M | $115M | $110M | $138M | · | $133M | $123M | $119M | · | $88M | |
| Other Current Assets | $360M | $330M | $339M | $323M | $314M | $304M | $348M | $231M | $252M | $251M | · | $236M | $217M | $190M | · | $268M | |
| Current Assets | $6.82B | $6.23B | $6.74B | $6.36B | $6.58B | $6.21B | $6.29B | $6.73B | $4.52B | $4.17B | · | $4.07B | $3.65B | $3.26B | · | $3.51B | |
| PP&E (Net) | $1.84B | $1.82B | $1.81B | $1.74B | $1.73B | $1.70B | $1.69B | $1.68B | $1.64B | $1.77B | · | $1.68B | $1.66B | $1.65B | · | $1.57B | |
| PP&E (Gross) | · | · | $2.66B | · | · | · | $2.48B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $850M | · | · | · | $794M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $1.95B | $1.82B | $1.77B | $1.77B | $1.78B | $1.78B | $1.78B | $1.61B | $1.15B | $1.25B | $1.15B | $1.30B | $1.30B | $1.31B | $1.06B | $1.16B | |
| Intangibles | $1.38B | $1.23B | $1.13B | $1.13B | $1.17B | $1.17B | $1.18B | $956M | $417M | $447M | · | $430M | $431M | $447M | · | $266M | |
| Other Non-current Assets | $616M | $739M | $730M | $785M | $743M | $743M | $722M | $684M | $790M | $768M | · | $447M | $412M | $294M | · | $316M | |
| Total Assets | $13.87B | $13.32B | $13.70B | $13.27B | $13.49B | $13.02B | $13.06B | $12.97B | $10.10B | $9.74B | · | $9.37B | $9.00B | $8.65B | · | $8.64B | |
| Accounts Payable | $210M | $181M | $228M | $165M | $162M | $172M | $197M | $173M | $186M | $212M | · | $191M | $193M | $181M | · | $155M | |
| Current Liabilities | $1.51B | $1.41B | $1.81B | $1.59B | $1.40B | $1.39B | $1.51B | $1.94B | $1.22B | $1.11B | · | $1.24B | $1.16B | $1.08B | · | $918M | |
| Capital Leases | $82M | $80M | $83M | $75M | $79M | $78M | $79M | $85M | $74M | $77M | · | $70M | $64M | $66M | · | $67M | |
| Other Non-current Liabilities | $382M | $351M | $362M | $363M | $379M | $358M | $373M | $323M | $257M | $266M | · | $240M | $243M | $260M | · | $221M | |
| Total Liabilities | $3.14B | $2.99B | $3.36B | $3.07B | $2.88B | $2.83B | $2.99B | $3.36B | $2.59B | $2.55B | · | $2.64B | $2.56B | $2.59B | · | $2.42B | |
| Total Debt | $599M | $598M | · | $598M | $598M | $598M | · | $598M | $597M | $597M | · | $597M | $597M | $596M | · | $596M | |
| Common Stock | $662M | $660M | $659M | $658M | $658M | $656M | $655M | $654M | $654M | $652M | · | $650M | $649M | $647M | · | $646M | |
| Retained Earnings | $14.86B | $14.62B | $14.24B | $14.15B | $13.86B | $13.53B | $13.17B | $12.78B | $9.71B | $9.34B | · | $8.62B | $8.24B | $7.93B | · | $7.19B | |
| Treasury Stock | $7.67B | $7.51B | $7.09B | $7.05B | $6.46B | $6.45B | $6.19B | $6.09B | $5.18B | $5.02B | · | $4.58B | $4.40B | $4.39B | · | $3.28B | |
| AOCI | $-215M | $-221M | $-238M | $-250M | $-264M | $-254M | $-244M | $-252M | $-220M | $-233M | · | $-250M | $-256M | $-255M | · | $-256M | |
| Stockholders' Equity | $10.62B | $10.33B | $10.34B | $10.21B | $10.55B | $10.13B | $10.00B | $9.55B | $7.44B | $7.12B | · | $6.66B | $6.38B | $5.98B | · | $6.22B | |
| Liabilities + Equity | $13.87B | $13.32B | $13.70B | $13.27B | $13.49B | $13.02B | $13.06B | $12.97B | $10.10B | $9.74B | · | $9.37B | $9.00B | $8.65B | · | $8.64B | |
| Shares Outstanding | 576,600,000 | 577,000,000 | 580,700,000 | 580,700,000 | 587,900,000 | 586,200,000 | 588,600,000 | 589,800,000 | 602,300,000 | 602,400,000 | 650,500,000 | 606,500,000 | 607,900,000 | 606,000,000 | 646,300,000 | 619,400,000 |
नकदी प्रवाह 13
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $43M | $41M | $43M | $39M | $38M | $37M | $43M | $34M | $40M | $38M | $37M | $37M | $36M | $35M | $35M | $35M | |
| Stock-based Comp | $42M | $45M | $39M | $41M | $38M | $40M | $32M | $42M | $44M | $45M | $30M | $33M | $37M | $39M | $28M | $30M | |
| Restructuring | · | · | $5M | $100.0K | · | · | $0 | $33M | · | · | · | $0 | · | · | · | · | |
| Other Non-cash | · | $-423M | · | · | · | $-154M | · | · | · | $-488M | · | · | · | · | · | · | |
| Operating Cash Flow | $652M | $44M | $451M | $574M | $290M | $280M | $-128M | $352M | $372M | $-54M | $137M | $412M | $34M | $314M | $283M | $310M | |
| CapEx | $67M | $65M | $97M | $58M | $49M | $56M | $50M | $52M | $85M | $65M | $88M | $55M | $48M | $62M | $69M | $60M | |
| Investing Cash Flow | $-193M | $-93M | $-198M | $-428M | $-172M | $85M | $-577M | $2.70B | $125M | $63M | $14M | $89M | $70M | $500.0K | $95M | $-202M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Stock Repurchased | $153M | $422M | $41M | $589M | $6M | $259M | $100M | $901M | $158M | $200.0K | $448M | $174M | $8M | $249M | $866M | $100M | |
| Net Stock Activity | · | $-422M | · | · | · | $-259M | · | · | · | $-200.0K | · | · | · | $-249M | · | · | |
| Financing Cash Flow | $-300.0K | $-451M | $-11M | $-740M | $53M | $-258M | $29M | $-977M | $-97M | $62M | $-413M | $-143M | $52M | $-207M | $-838M | $-70M | |
| Net Change in Cash | $462M | $-492M | $245M | $-595M | $141M | $90M | $-625M | $2.03B | $429M | $81M | $-266M | $366M | $171M | $104M | $-479M | $49M | |
| Free Cash Flow | · | $-21M | · | · | · | $224M | · | · | · | $-119M | · | · | · | $253M | · | · |
लाभप्रदता 8
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.5% | 78.0% | · | 77.8% | 77.5% | 78.6% | · | 80.6% | 79.4% | 75.9% | · | 76.3% | 77.6% | 77.4% | · | 80.8% | |
| Operating Margin | 29.5% | 29.0% | · | 19.8% | 26.8% | 28.0% | · | 25.9% | 26.6% | 24.2% | · | 28.2% | 21.4% | 26.6% | · | 30.5% | |
| Net Margin | 13.9% | 23.1% | · | 18.7% | 21.8% | 25.3% | · | 226.7% | 26.4% | 22.0% | · | 26.0% | 20.1% | · | · | · | |
| Pretax Margin | 29.9% | 27.8% | · | 22.4% | 26.1% | 30.7% | · | 29.7% | 27.9% | 25.6% | · | 29.7% | 22.1% | 27.3% | · | 30.9% | |
| EBITDA Margin | 29.5% | 31.4% | · | 19.8% | 26.8% | 30.5% | · | 25.9% | 26.6% | 26.7% | · | 28.2% | 21.4% | 29.0% | · | 30.5% | |
| ROA | 1.8% | 2.9% | · | 2.2% | 2.8% | 3.1% | · | 27.5% | 3.8% | 3.8% | · | 4.3% | 3.5% | · | · | · | |
| ROE | 2.3% | 3.7% | · | 2.9% | 3.7% | 4.2% | · | 37.9% | 5.3% | 5.4% | · | 6.0% | 5.0% | · | · | · | |
| ROIC | 2.1% | 3.6% | · | 2.4% | 3.1% | 3.1% | · | 3.1% | 4.3% | 4.3% | · | 5.0% | 4.2% | 5.1% | · | 5.0% |
तरलता और शोधन क्षमता 4
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 4.4 | · | 4.0 | 4.7 | 4.5 | · | 3.5 | 3.7 | 3.8 | · | 3.3 | 3.2 | 3.0 | · | 3.8 | |
| Quick Ratio | 3.3 | 3.2 | · | 2.9 | 3.4 | 3.3 | · | 2.7 | 2.3 | 2.3 | · | 2.1 | 2.0 | 1.8 | · | 2.6 | |
| Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| LT Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 |
दक्षता 3
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.2 | 0.3 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.3 | |
| Receivables Turnover | 2.4 | 2.3 | · | 2.2 | 2.1 | 1.9 | · | 1.9 | 1.8 | 2.1 | · | 2.2 | 2.2 | 2.2 | · | 2.2 |
मूल्यांकन (TTM) 14
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6.47B | $6.15B | · | $5.88B | $5.69B | $5.52B | · | $5.32B | $5.21B | $5.12B | · | $5.06B | $5.19B | $5.26B | · | $5.34B | |
| Net Income TTM | $1.25B | $1.36B | · | $1.37B | $4.15B | $4.18B | · | $4.16B | $1.47B | $1.41B | · | $1.38B | $1.40B | · | · | · | |
| Market Cap | $52.16B | $46.21B | · | $45.16B | $45.98B | $42.49B | · | $38.92B | $55.63B | $57.57B | · | $42.02B | $57.34B | $50.13B | · | $51.18B | |
| Enterprise Value | $48.51B | $43.13B | · | $41.92B | $42.52B | $39.19B | · | $35.07B | $54.24B | $56.46B | · | $40.75B | $56.43B | $49.48B | · | $50.04B | |
| P/E | 42.3 | 34.4 | · | 33.5 | 11.3 | 10.4 | · | 9.5 | 38.0 | 41.2 | · | 30.9 | 41.7 | 35.2 | · | 35.5 | |
| P/S | 8.1 | 7.5 | · | 7.7 | 8.1 | 7.7 | · | 7.3 | 10.7 | 11.2 | · | 8.3 | 11.0 | 9.5 | · | 9.6 | |
| P/B | 4.9 | 4.5 | · | 4.4 | 4.4 | 4.2 | · | 4.1 | 7.5 | 8.1 | · | 6.3 | 9.0 | 8.4 | · | 8.2 | |
| P / Tangible Book | 7.2 | 6.3 | · | 6.2 | 6.1 | 5.9 | · | 5.6 | 9.5 | 10.6 | · | 8.5 | 12.3 | 11.9 | · | 10.7 | |
| P / Cash Flow | · | 1054.9 | · | · | · | 151.5 | · | · | · | -1076.0 | · | · | · | 159.6 | · | · | |
| P / FCF | · | -2189.9 | · | · | · | 189.3 | · | · | · | -484.6 | · | · | · | 198.5 | · | · | |
| EV / EBITDA | 94.5 | 83.2 | · | 136.5 | 103.4 | 90.8 | · | 100.0 | 147.0 | 132.5 | · | 97.4 | 172.5 | 116.8 | · | 124.4 | |
| EV / FCF | · | -2044.2 | · | · | · | 174.6 | · | · | · | -475.3 | · | · | · | 195.9 | · | · | |
| EV / Revenue | 7.5 | 7.0 | · | 7.1 | 7.5 | 7.1 | · | 6.6 | 10.4 | 11.0 | · | 8.0 | 10.9 | 9.4 | · | 9.4 | |
| Earnings Yield | 2.4% | 2.9% | · | 3.0% | 8.9% | 9.7% | · | 10.5% | 2.6% | 2.4% | · | 3.2% | 2.4% | 2.8% | · | 2.8% |
वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष
आय विवरण
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| राजस्व | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B |
| सकल मार्जिन % | 78.0% | 79.5% | 77.0% | 79.9% | 76.1% |
| परिचालन मार्जिन % | 20.8% | 25.4% | 25.6% | 32.5% | 32.3% |
| शुद्ध आय | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B |
| तनुकरणित EPS | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 |
बैलेंस शीट
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| ऋण / इक्विटी | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| वर्तमान अनुपात | 3.7 | 4.2 | 3.4 | 3.0 | 3.1 |
| त्वरित अनुपात | 2.7 | 3.0 | 2.0 | 1.8 | 2.0 |
नकदी प्रवाह
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| फ्री कैश फ्लो | $1.33B | $290M | $643M | $974M | $1.41B |
मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ
उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर पूर्ण फंडामेंटल में किसी भी पंक्ति के बगल में ➕ पर क्लिक करें।
आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।
संस्थागत मालिक (13F) 1444 फाइलर्स · $30.3B कुल · तिथि अनुसार 30 जून 2026
संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।
| नई स्थितियाँ | बाहर निकली पोजीशन | बढ़ाया | घटा हुआ | शुद्ध शेयर परिवर्तन |
|---|---|---|---|---|
| 152 (+6 पिछली तिमाही की तुलना में) | 97 (-10 पिछली तिमाही की तुलना में) | 459 (+11 पिछली तिमाही की तुलना में) | 452 (+4 पिछली तिमाही की तुलना में) | +26.4M |
Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।
| संस्था | मूल्य | शेयर | % ट्रैक किए गए 13F का | प्रकार |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $3402739018 | 37615952 | 11.25% | शेयर |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2389175425 | 26411402 | 7.90% | शेयर |
| STATE STREET CORP | $2381082692 | 26321940 | 7.87% | शेयर |
| WELLINGTON MANAGEMENT GROUP LLP | $1430999585 | 15819142 | 4.73% | शेयर |
| GEODE CAPITAL MANAGEMENT, LLC | $1219437867 | 13541730 | 4.03% | शेयर |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $1135640991 | 12554068 | 3.75% | शेयर |
| Ninety One UK Ltd | $1116050276 | 12337502 | 3.69% | शेयर |
| Aristotle Capital Management, LLC | $783906442 | 8665712 | 2.59% | शेयर |
| NORGES BANK | $757492410 | 8373783 | 2.50% | शेयर |
| ALLIANCEBERNSTEIN L.P. | $693526113 | 8660416 | 2.29% | शेयर |
| FMR LLC | $607177379 | 6712109 | 2.01% | शेयर |
| Artisan Partners Limited Partnership | $599361052 | 6625703 | 1.98% | शेयर |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $513572538 | 5677344 | 1.70% | शेयर |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | $434208000 | 4800000 | 1.44% | शेयर |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $334052859 | 3692824 | 1.10% | शेयर |
| MILLENNIUM MANAGEMENT LLC | $324280556 | 3584795 | 1.07% | शेयर |
| CITADEL ADVISORS LLC | $308338066 | 3408557 | 1.02% | शेयर |
| PRIMECAP MANAGEMENT CO/CA/ | $308314004 | 3408291 | 1.02% | शेयर |
| DIMENSIONAL FUND ADVISORS LP | $298865427 | 3303843 | 0.99% | शेयर |
| BROWN ADVISORY INC | $295062880 | 3261805 | 0.98% | शेयर |
| VANGUARD FIDUCIARY TRUST CO | $292399738 | 3232365 | 0.97% | शेयर |
| Holocene Advisors, LP | $283979721 | 3139285 | 0.94% | शेयर |
| NEUBERGER BERMAN GROUP LLC | $255069412 | 2818763 | 0.84% | शेयर |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $250776107 | 2772232 | 0.83% | शेयर |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $238277000 | 2634054 | 0.79% | शेयर |
| Mirova US LLC | $229802865 | 2540381 | 0.76% | शेयर |
| BANK OF AMERICA CORP /DE/ | $170884489 | 1889061 | 0.56% | शेयर |
| BlackRock, Inc. | $168018323 | 1857377 | 0.56% | शेयर |
| Assenagon Asset Management S.A. | $163997286 | 1812926 | 0.54% | शेयर |
| Point72 Asset Management, L.P. | $160486895 | 1774120 | 0.53% | शेयर |
| RAYMOND JAMES FINANCIAL INC | $152806000 | 1689211 | 0.51% | शेयर |
| Swiss National Bank | $147097006 | 1626100 | 0.49% | शेयर |
| Woodline Partners LP | $141123209 | 1560062 | 0.47% | शेयर |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $140351128 | 1551434 | 0.46% | शेयर |
| TWO SIGMA INVESTMENTS, LP | $137670984 | 1521899 | 0.46% | शेयर |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $131472173 | 1453357 | 0.43% | शेयर |
| Mitsubishi UFJ Asset Management Co., Ltd. | $126120870 | 1394217 | 0.42% | शेयर |
| Legal & General Group Plc | $121108845 | 1338811 | 0.40% | शेयर |
| ROYAL BANK OF CANADA | $119193000 | 1317637 | 0.39% | शेयर |
| Sumitomo Mitsui Trust Group, Inc. | $113885341 | 1258958 | 0.38% | शेयर |
| Quantinno Capital Management LP | $113292795 | 1252407 | 0.37% | शेयर |
| Vanguard Global Advisers, LLC | $112247472 | 1240852 | 0.37% | शेयर |
| Liontrust Investment Partners LLP | $110033644 | 1216379 | 0.36% | शेयर |
| VANGUARD GROUP INC | $107656172 | 1262829 | 0.36% | शेयर |
| SEB Asset Management AB | $106981085 | 1182636 | 0.35% | शेयर |
| VANGUARD ASSET MANAGEMENT, Ltd | $100522409 | 1111236 | 0.33% | शेयर |
| Polar Capital Holdings Plc | $99945636 | 1104860 | 0.33% | शेयर |
| RHUMBLINE ADVISERS | $99213696 | 1096770 | 0.33% | शेयर |
| BNP PARIBAS FINANCIAL MARKETS | $92822996 | 1026122 | 0.31% | शेयर |
| PARNASSUS INVESTMENTS, LLC | $91873890 | 1015630 | 0.30% | शेयर |
| Bank of New York Mellon Corp | $91654072 | 1013200 | 0.30% | शेयर |
| National Pension Service | $90349187 | 998775 | 0.30% | शेयर |
| California Public Employees Retirement System | $89091250 | 984869 | 0.29% | शेयर |
| Caisse de depot et placement du Quebec | $87523397 | 967537 | 0.29% | शेयर |
| ABN AMRO Bank N.V. | $83573385 | 924314 | 0.28% | शेयर |
| GOLDMAN SACHS GROUP INC | $82454109 | 911498 | 0.27% | शेयर |
| Empower Advisory Group, LLC | $80384543 | 888620 | 0.27% | शेयर |
| Meridiem Capital Partners LP | $77697994 | 858921 | 0.26% | शेयर |
| Man Group plc | $76372212 | 844265 | 0.25% | शेयर |
| ORBIMED ADVISORS LLC | $75525054 | 834900 | 0.25% | शेयर |
| Alyeska Investment Group, L.P. | $73531316 | 812860 | 0.24% | शेयर |
| Nantahala Capital Management, LLC | $72368000 | 800000 | 0.24% | पुट ऑप्शन |
| CANADA PENSION PLAN INVESTMENT BOARD | $72254020 | 798740 | 0.24% | शेयर |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $69805736 | 871700 | 0.23% | शेयर |
| ENVESTNET ASSET MANAGEMENT INC | $66940606 | 740002 | 0.22% | शेयर |
| Bellevue Group AG | $66871108 | 739234 | 0.22% | शेयर |
| Birch Hill Investment Advisors LLC | $66522203 | 735377 | 0.22% | शेयर |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $64772074 | 716030 | 0.21% | शेयर |
| TD Asset Management Inc | $61560472 | 680527 | 0.20% | शेयर |
| PRINCIPAL FINANCIAL GROUP INC | $61491904 | 679769 | 0.20% | शेयर |
| UBS Group AG | $60908889 | 673324 | 0.20% | शेयर |
| Candriam S.C.A. | $59988129 | 663784 | 0.20% | शेयर |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $57604363 | 675711 | 0.19% | शेयर |
| Integral Health Asset Management, LLC | $56537500 | 625000 | 0.19% | शेयर |
| Ninety One North America, Inc. | $55768413 | 616498 | 0.18% | शेयर |
| Robeco Institutional Asset Management B.V. | $55270246 | 610991 | 0.18% | शेयर |
| Seilern Investment Management Ltd | $54296896 | 600231 | 0.18% | शेयर |
| Nan Shan Life Insurance Co., Ltd. | $49953912 | 552221 | 0.17% | शेयर |
| PFA Pension, Forsikringsaktieselskab | $49175025 | 543611 | 0.16% | शेयर |
| BARCLAYS PLC | $49135520 | 543174 | 0.16% | शेयर |
| Triodos Investment Management BV | $44629165 | 493358 | 0.15% | शेयर |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $44266149 | 489345 | 0.15% | शेयर |
| Mitsubishi UFJ Trust & Banking Corp | $43182890 | 477370 | 0.14% | शेयर |
| APG Asset Management N.V. | $42840046 | 541444 | 0.14% | शेयर |
| United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund | $42480287 | 469603 | 0.14% | शेयर |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $42097461 | 465371 | 0.14% | शेयर |
| AVIVA PLC | $41577497 | 459623 | 0.14% | शेयर |
| Balyasny Asset Management L.P. | $41248584 | 455987 | 0.14% | शेयर |
| Korea Investment CORP | $40486097 | 447558 | 0.13% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $39585296 | 437600 | 0.13% | कॉल ऑप्शन |
| NORDEA INVESTMENT MANAGEMENT AB | $37761927 | 418322 | 0.12% | शेयर |
| STOREBRAND ASSET MANAGEMENT AS | $37671343 | 416442 | 0.12% | शेयर |
| Qube Research & Technologies Ltd | $37490061 | 414438 | 0.12% | शेयर |
| OFI INVEST ASSET MANAGEMENT | $36480086 | 458427 | 0.12% | शेयर |
| Fisher Funds Management LTD | $35971057 | 397646 | 0.12% | शेयर |
| LPL Financial LLC | $34985891 | 386755 | 0.12% | शेयर |
| ABN AMRO INVESTMENT SOLUTIONS | $33668217 | 372189 | 0.11% | शेयर |
| AMERIPRISE FINANCIAL INC | $32517021 | 359463 | 0.11% | शेयर |
| BLAIR WILLIAM & CO/IL | $32206687 | 356032 | 0.11% | शेयर |
| Champlain Investment Partners, LLC | $31357054 | 346640 | 0.10% | शेयर |
कंपनी के अंदरूनी सूत्र 48 इनसाइडर्स · 18 अधिकारी · 8 निदेशक
| अंदरूनी | भूमिका | अंतिम गतिविधि | शेयरों का स्वामित्व | खरीद 12m | बिक्री 12m | नेट 12m |
|---|---|---|---|---|---|---|
| Bernard J Zovighian | CEO | 27 जुलाई 2026 S | 8916 | 0 | 8 | $-6996971 |
| Theodora Mistras | CVP, Chief Financial Officer | 9 जुलाई 2026 A | 99920 | 0 | 0 | $0 |
| Thomas M Abate | CVP, CFO | 14 मई 2013 A | 43047 | 0 | 0 | $0 |
| Wayne Markowitz | CVP, JAPAC | 30 जुलाई 2026 S | 21534 | 0 | 4 | $-928942 |
| Annette Bruls | CVP, EMEACLA | 11 जुलाई 2026 F | 20628 | 0 | 0 | $0 |
| Andrew M. Dahl | SVP, Corporate Controller | 29 मई 2026 S | 15334 | 0 | 1 | $-48893 |
| Carlyn D Solomon | CVP, Critical Care & Vascular | 28 अक्टूबर 2014 M | 31154 | 0 | 0 | $0 |
| Christine Z Mccauley | CVP, Human Resources | 13 मई 2013 F | 4035 | 0 | 0 | $0 |
| Paul C Redmond | CVP, Global Operations | 13 मई 2013 S | 12534 | 0 | 0 | $0 |
| Bruce P Garren | CVP, Public Affairs/Special Co | 13 मई 2013 F | 56071 | 0 | 0 | $0 |
| John H Kehl JR | CVP, Strategy & Corp Dev | 7 मई 2013 F | 101767 | 0 | 0 | $0 |
| Robert C Reindl | CVP, H.R. and Communications | 27 जुलाई 2012 M | 1124 | 0 | 0 | $0 |
| Aimee S Weisner | CVP, General Counsel | 9 मई 2012 A | 1675 | 0 | 0 | $0 |
| Corinne H Nevinny | CVP & Pres., Global Ops | 13 मई 2010 A | 16687 | 0 | 0 | $0 |
| Anita Bessler | CVP | 31 अगस्त 2007 S | 29410 | 0 | 0 | $0 |
| John Alexander Martin | CVP, North America | 10 मई 2007 A | 15300 | 0 | 0 | $0 |
| Stuart L Foster | CVP, Critical Care / Vascular | 10 मई 2007 A | 24604 | 0 | 0 | $0 |
| Randel William Woodgrift | Corp VP, Manufacturing Ops | 4 अगस्त 2005 M | 3349 | 0 | 0 | $0 |
| John T Cardis | निदेशक | 10 अगस्त 2016 S | 91458 | 0 | 0 | $0 |
| Barbara J Mcneil | निदेशक | 4 फ़रवरी 2016 S | 46454 | 0 | 0 | $0 |
| Robert Alexander Ingram | निदेशक | 15 मई 2015 A | 32367 | 0 | 0 | $0 |
| Michael R Bowlin | निदेशक | 14 नवमबर 2014 M | 81751 | 0 | 0 | $0 |
| David E I Pyott | निदेशक | 9 मई 2014 A | 53582 | 0 | 0 | $0 |
| NEAL PHILIP M | निदेशक | 12 अगस्त 2008 M | 27333 | 0 | 0 | $0 |
| Vernon R Loucks JR | निदेशक | 9 मई 2008 A | 24133 | 0 | 0 | $0 |
| Daniel J. Lippis | — | 11 अगस्त 2026 M | 40034 | 0 | 12 | $-817452 |
| Donald E Bobo JR | — | 27 मई 2026 S | 98611 | 0 | 12 | $-11153294 |
| Daveen Chopra | — | 22 मई 2026 S | 44324 | 0 | 3 | $-500535 |
| Scott B. Ullem | — | 11 मई 2026 M | 46740 | 0 | 7 | $-3875008 |
| Leslie C. Davis | — | 8 मई 2026 A | 9834 | 0 | 0 | $0 |
| Ramona Sequeira | — | 8 मई 2026 A | 6779 | 0 | 0 | $0 |
| David T Feinberg | — | 8 मई 2026 A | 9087 | 0 | 0 | $0 |
| Kieran Gallahue | — | 8 मई 2026 A | 4315 | 0 | 0 | $0 |
| Nicholas J Valeriani | — | 8 मई 2026 A | 84423 | 0 | 0 | $0 |
| Heisz Leslie Stone | — | 8 मई 2026 A | 34199 | 0 | 1 | $-218117 |
| Steven R Loranger | — | 8 मई 2026 A | 8997 | 0 | 0 | $0 |
| Paul A Laviolette | — | 8 मई 2026 A | 17552 | 0 | 0 | $0 |
| Larry L Wood | — | 18 अगस्त 2025 M | 206900 | 0 | 0 | $0 |
| Catherine M. Szyman | — | 3 सितमबर 2024 F | 81287 | 0 | 0 | $0 |
| Jean-Luc M Lemercier | — | 7 जुलाई 2024 F | 184686 | 0 | 0 | $0 |
| Robert W.A. Sellers | — | 11 मई 2024 F | 17081 | 0 | 0 | $0 |
| Michael A Mussallem | — | 2 मई 2024 M | 4486 | 0 | 0 | $0 |
| Martha H. Marsh | — | 12 मई 2023 A | 31880 | 0 | 0 | $0 |
| Huimin Wang | — | 8 जुलाई 2022 M | 99381 | 0 | 0 | $0 |
| William J Link PHD | — | 8 मई 2020 A | 11349 | 0 | 0 | $0 |
| Wesley W Von Schack | — | 1 अगस्त 2019 S | 8000 | 0 | 0 | $0 |
| Patrick B Verguet | — | 31 मई 2017 M | 129137 | 0 | 0 | $0 |
| Randall J Nelson | — | 30 सितमबर 2003 A | — | 0 | 0 | $0 |
SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S
कार्यकर्ता और 5%+ मालिक 1 होल्डिंग
जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।
| फाइलर | दाखिल किया | दांव | स्थिति | उद्देश्य | फाइलिंग |
|---|---|---|---|---|---|
| अघोषित रिपोर्टिंग व्यक्ति | 5 अप्रैल 2001 | — | प्रारंभिक फाइलिंग | बोर्ड अभियान | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ईटीएफ स्वामित्व 180 ETFs द्वारा धारित
वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।
| फंड | भार | इकाइयाँ | तिथि अनुसार | स्रोत |
|---|---|---|---|---|
| IHI · iShares Trust | 4.29% | 1607851 SH | 8 अगस्त 2026 | दैनिक |
| GDOC · Goldman Sachs ETF Trust | 2.98% | 6939 NS | 31 मई 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 2.11% | 10000 NS | 31 मई 2026 | N-PORT |
| ANEW · ProShares Trust | 2.02% | 1801 NS | 31 मई 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 1.83% | 2435 NS | 30 अप्रैल 2026 | N-PORT |
| PJBF · PGIM ETF Trust | 1.75% | 2374 NS | 29 मई 2026 | N-PORT |
| HRTS · Tema ETF Trust | 1.75% | 10488 NS | 31 मई 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.58% | 137940 SH | 8 अगस्त 2026 | दैनिक |
| VOT · VANGUARD INDEX FUNDS | 1.14% | 4411246 SH | 8 अगस्त 2026 | दैनिक |
| ALTL · Pacer Funds Trust | 0.94% | 10780 NS | 30 अप्रैल 2026 | N-PORT |
| CVAR · ETF Opportunities Trust | 0.93% | 4325 NS | 30 अप्रैल 2026 | N-PORT |
| SDG · iShares Trust | 0.90% | 17447 SH | 8 अगस्त 2026 | दैनिक |
| FFND · Northern Lights Fund Trust II | 0.88% | 10459 NS | 31 मई 2026 | N-PORT |
| IYH · iShares Trust | 0.83% | 341366 SH | 8 अगस्त 2026 | दैनिक |
| BKDV · BNY Mellon ETF Trust II | 0.81% | 134666 NS | 30 अप्रैल 2026 | N-PORT |
| NULV · Nushares ETF Trust | 0.79% | 197378 NS | 30 अप्रैल 2026 | N-PORT |
| JOET · Virtus ETF Trust II | 0.79% | 22410 NS | 30 अप्रैल 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.78% | 267514 NS | 30 अप्रैल 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.77% | 1733147 SH | 8 अगस्त 2026 | दैनिक |
| NULC · Nushares ETF Trust | 0.75% | 5090 NS | 30 अप्रैल 2026 | N-PORT |
| RXL · ProShares Trust | 0.73% | 6052 NS | 31 मई 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0.70% | 11571 NS | 30 अप्रैल 2026 | N-PORT |
| IMCG · iShares Trust | 0.66% | 301692 SH | 8 अगस्त 2026 | दैनिक |
| IXJ · iShares Trust | 0.65% | 302050 SH | 8 अगस्त 2026 | दैनिक |
| TEC · Harbor ETF Trust | 0.61% | 491 NS | 30 अप्रैल 2026 | N-PORT |
| FWD · AB Active ETFs, Inc. | 0.56% | 187544 NS | 31 मई 2026 | N-PORT |
| HUSV · First Trust Exchange-Traded Fund III | 0.56% | 4857 NS | 30 अप्रैल 2026 | N-PORT |
| BRNY · EA Series Trust | 0.54% | 35555 NS | 30 अप्रैल 2026 | N-PORT |
| AVMC · AMERICAN CENTURY ETF TRUST | 0.53% | 24654 NS | 31 मई 2026 | N-PORT |
| SUSA · iShares Trust | 0.51% | 237552 SH | 8 अगस्त 2026 | दैनिक |
| VO · VANGUARD INDEX FUNDS | 0.50% | 12477902 SH | 8 अगस्त 2026 | दैनिक |
| IWS · iShares Trust | 0.49% | 860071 SH | 8 अगस्त 2026 | दैनिक |
| FXH · First Trust Exchange-Traded AlphaDE… | 0.42% | 44305 NS | 30 अप्रैल 2026 | N-PORT |
| HELO · J.P. Morgan Exchange-Traded Fund Tr… | 0.40% | 193493 NS | 30 अप्रैल 2026 | N-PORT |
| JOYT · J.P. Morgan Exchange-Traded Fund Tr… | 0.37% | 3768 NS | 30 अप्रैल 2026 | N-PORT |
| IWR · iShares Trust | 0.36% | 2320860 SH | 8 अगस्त 2026 | दैनिक |
| IMCB · iShares Trust | 0.34% | 63843 SH | 8 अगस्त 2026 | दैनिक |
| JGLO · J.P. Morgan Exchange-Traded Fund Tr… | 0.34% | 286558 NS | 30 अप्रैल 2026 | N-PORT |
| EVUS · iShares Trust | 0.31% | 12935 SH | 8 अगस्त 2026 | दैनिक |
| NBCR · Neuberger Berman ETF Trust | 0.30% | 30404 NS | 31 मई 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.29% | 156342 SH | 8 अगस्त 2026 | दैनिक |
| XOEF · iShares Trust | 0.28% | 720 SH | 8 अगस्त 2026 | दैनिक |
| ESUM · Strategy Shares | 0.27% | 5033 NS | 30 अप्रैल 2026 | N-PORT |
| DFLV · Dimensional ETF Trust | 0.27% | 189108 NS | 30 अप्रैल 2026 | N-PORT |
| WINN · Harbor ETF Trust | 0.24% | 31226 NS | 30 अप्रैल 2026 | N-PORT |
| DEUS · DBX ETF Trust | 0.24% | 7428 NS | 29 मई 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0.23% | 887 NS | 30 अप्रैल 2026 | N-PORT |
| FFLG · FIDELITY COVINGTON TRUST | 0.22% | 15544 NS | 30 अप्रैल 2026 | N-PORT |
| CAPE · DoubleLine ETF Trust | 0.22% | 7122 NS | 31 मार्च 2026 | N-PORT |
| GSEW · Goldman Sachs ETF Trust | 0.21% | 42168 NS | 31 मई 2026 | N-PORT |